Vancouver, BC - TheNewswire - November 29, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC:AQSZF) (“Aequus” or the “Company ”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended September 30, 2023 (“Third Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in... Read More

Vancouver, BC - TheNewswire - October 20, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC: AQSZF) (“ Aequus ” or the “ Company ”), announces today it has increased its debt by $1,000,000 to support operating costs and the new sales of Zimed ® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of advanced funds on the same general conditions as... Read More

VANCOUVER, BC – TheNewswire - October 6, 2023 - Aequus Pharmaceuticals Inc. (TSXV:AQS ) , ( OTC:AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $270,000 to support operating costs andthe new sales of Zimed ® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$270,000 (the “ Loan ”). The... Read More

VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are... Read More

VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed ® PF , the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. "This marks a new growth phase for Aequus and the launch of a Preservative Free (PF)... Read More

VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals. With a focus on elevated, interocular pressure, Glaucoma and Dry Eye Disease, this website features Zimed ® PF, the first... Read More

VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing... Read More

VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed ® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$400,000 (the “ Loan ”). The Loan bears... Read More

VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are... Read More

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the year ended December 31, 2022 (“Fiscal 2022”) and associated Company developments. Unless otherwise noted, all figures... Read More

VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”), announces that it has granted incentive stock options (the “Options”) to certain directors, officers, employees, and consultants of the Company to purchase up to an aggregate of 2,775,000 common shares of the Company. These stock options are exercisable at a price of $0.03... Read More

VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today it has entered into a loan agreement to raise $500,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, will provide financing to Aequus by way of an unsecured demand loan of C$500,000 (the “ Loan ”). The... Read More

VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed ® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading... Read More

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all... Read More

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to end its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on Tacrolimus Immediate Release (Immunosuppressant/Transplant) (“Tacrolimus IR”) and Pr Vistitan™ (bimatoprost 0.03% ophthalmic solution), effective December 31, 2022.... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, has hired Rabin Ramanjooloo as Director of Operations and today reported financial results for the quarter ended June 30, 2022 (“Second Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trading on the TSX Venture exchange tomorrow, July 14, 2022. Doug Janzen noted that “We will be taking steps to lower the risk of this ever happening again. We are excited about the new Scope products announced last week and plan to have other items to add to our product menu in the coming... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with SCOPE Ophthalmics. (“SCOPE”), an Irish based eyecare company with a focus on preservative free therapies in ophthalmology. Under the distribution agreement, Aequus will receive the Canadian commercial rights to 10 unique products of SCOPE’s portfolio of... Read More

Also reports Financial Results for the 3 months ended March 31, 2022 Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues from direct product sales and profit share arrangements, today reported financial results for the year ended... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”) announces that further to its news release on May 6, 2022 and May 26, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and the related management’s discussion and analysis (collectively, the “ Annual Disclosure ”) as well at the financial statements for the three months ended March 31,... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ) (“ Aequus ” or the “ Company ”) announces that further to its news release on May 6, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its management’s discussion and analysis relating to the Annual Financial Statements (collectively, the “ Annual Disclosure ”) continues to be delayed. Doug Janzen, CEO and... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”) announces that further to its news release on May 2, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its management’s discussion and analysis relating to the Annual Financial Statements (collectively, the “ Annual Disclosure ”) continues to be delayed and we now expect to receive... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”) announces that the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and its management’s discussion and analysis relating to the Annual Financial Statements (collectively, the “ Annual Disclosure ”) will be delayed beyond the filing deadline of May 2, 2022. The Company’s late filing of the... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “ Company ”) announces that it has entered into an agreement with Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, pursuant to which Mr. Janzen will provide short-term financing to Aequus by way of an unsecured demand loan of C$2 million (the “ Loan ”). The purpose of the financing is to allow the Company to pay off the existing... Read More

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announces that Mr. Jason Flowerday has resigned from the Aequus Board of Directors. Douglas Janzen, Aequus’ Chair & Chief Executive Officer, stated: “We are excited for Jason and his new business ventures. We wish him the best and want to thank him for all his... Read More